v3.26.1
Segment information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment information

Note 8. Segment information

 

The Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neuropathic pain, inflammatory pain, weight management, and addiction-related disorders. The CODM for the Company is the Chief Executive Officer (the “CEO”). The CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

 

 

MIRA PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

 

The accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies within Note 1. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that is also reported on the income statement as net loss. The measure of segment assets is reported on the balance sheets as total assets.

 

The table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 

   2026   2025    2026     2025  
   For the three months ended June 30,   

For the six months ended June 30,

  
   2026   2025    2026     2025  
Revenues  $—   $—    $ —     $ —  
                           
Operating costs:                          
General and administrative expenses   450,330    1,049,903     

1,029,028

      

2,540,699

  
Research and development expenses   705,789    496,197     

1,230,570

      

810,601

  
Total operating costs   1,156,119    1,546,100     

2,259,598

      

3,351,300

  
                           
Other income (expense):                          
Interest income   35,130    8,623     

80,038

      

30,044

  
Other expense   

—

    

(235

)    

—

       (235 )
Loss from equity method investments   (87,545)   —     

(179,126

 )    

—

  
Total other income (expense), net   (52,415)   8,388     

(99,088

 )    

29,809

  
Segment net loss 

$

(1,208,534) 

$

(1,537,712)  

$

(2,358,686

 )  

$

(3,321,491

 )